Here's What Key Metrics Tell Us About Collegium Pharmaceutical (COLL) Q3 Earnings

Collegium Pharmaceutical (COLL) reported $159.3 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 16.5%. EPS of $1.61 for the same period compares to $1.34 a year ago.The reported revenue represents a surprise of -0.43% over the Zacks Consensus Estimate of $159.99 million. With the consensus EPS estimate being $1.66, the EPS surprise was -3.01%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.Here is how Collegium Pharmaceutical performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Total product revenues- Belbuca: $53.20 million compared to the $52.53 million average estimate based on three analysts. The reported number represents a change of +17.1% year over year. Total product revenues- Nucynta: $45.13 million versus $43.34 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -5.1% change. Total product revenues- Symproic: $3.57 million compared to the $3.77 million average estimate based on three analysts. The reported number represents a change of -9% year over year. Total product revenues- Xtampza ER: $49.49 million versus $47.45 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +24.4% change. View all Key Company Metrics for Collegium Pharmaceutical here>>>Shares of Collegium Pharmaceutical have returned -8.2% over the past month versus the Zacks S&P 500 composite's +3.2% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.Free Today: Profiting from The Future’s Brightest Energy SourceThe demand for electricity is growing exponentially. At the same time, we’re working to reduce our dependence on fossil fuels like oil and natural gas. Nuclear energy is an ideal replacement.Leaders from the US and 21 other countries recently committed to TRIPLING the world’s nuclear energy capacities. This aggressive transition could mean tremendous profits for nuclear-related stocks – and investors who get in on the action early enough.Our urgent report, Atomic Opportunity: Nuclear Energy's Comeback, explores the key players and technologies driving this opportunity, including 3 standout stocks poised to benefit the most.Download Atomic Opportunity: Nuclear Energy's Comeback free today.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Collegium Pharmaceutical, Inc. (COLL): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks